1. Home
  2. IDYA vs VAC Comparison

IDYA vs VAC Comparison

Compare IDYA & VAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • VAC
  • Stock Information
  • Founded
  • IDYA 2015
  • VAC 1984
  • Country
  • IDYA United States
  • VAC United States
  • Employees
  • IDYA N/A
  • VAC N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • VAC Real Estate
  • Sector
  • IDYA Health Care
  • VAC Finance
  • Exchange
  • IDYA Nasdaq
  • VAC Nasdaq
  • Market Cap
  • IDYA 1.9B
  • VAC 2.2B
  • IPO Year
  • IDYA 2019
  • VAC N/A
  • Fundamental
  • Price
  • IDYA $21.23
  • VAC $72.30
  • Analyst Decision
  • IDYA Strong Buy
  • VAC Buy
  • Analyst Count
  • IDYA 13
  • VAC 8
  • Target Price
  • IDYA $53.42
  • VAC $92.25
  • AVG Volume (30 Days)
  • IDYA 1.1M
  • VAC 723.5K
  • Earning Date
  • IDYA 08-05-2025
  • VAC 07-30-2025
  • Dividend Yield
  • IDYA N/A
  • VAC 4.38%
  • EPS Growth
  • IDYA N/A
  • VAC 7.38
  • EPS
  • IDYA N/A
  • VAC 5.85
  • Revenue
  • IDYA $7,000,000.00
  • VAC $3,301,000,000.00
  • Revenue This Year
  • IDYA $101.20
  • VAC $55.83
  • Revenue Next Year
  • IDYA $286.70
  • VAC $3.54
  • P/E Ratio
  • IDYA N/A
  • VAC $12.34
  • Revenue Growth
  • IDYA N/A
  • VAC 4.26
  • 52 Week Low
  • IDYA $13.45
  • VAC $49.22
  • 52 Week High
  • IDYA $44.42
  • VAC $100.32
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 62.23
  • VAC 62.83
  • Support Level
  • IDYA $21.08
  • VAC $67.46
  • Resistance Level
  • IDYA $22.37
  • VAC $74.74
  • Average True Range (ATR)
  • IDYA 0.92
  • VAC 1.90
  • MACD
  • IDYA -0.09
  • VAC 0.49
  • Stochastic Oscillator
  • IDYA 61.72
  • VAC 76.24

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About VAC Marriott Vacations Worldwide Corporation

Marriott Vacations Worldwide Corp functions in the United States leisure industry. It owns and manages a cluster of resorts and accommodation facilities under trademarks like Marriott Vacation Club, Grand Residencies, and The Ritz-Carlton Destination Club predominantly in the United States. Some of its properties are also spread across Europe and Asia Pacific. Marriott's majority revenue components include the sale of vacation ownership products such as luxurious vacation packages. In addition, it offers purchase money financing to the end users of its core services. The company operates in two reportable segments: Vacation Ownership and Exchange & Third-Party Management. The majority of revenue is derived from the Vacation Ownership segment.

Share on Social Networks: